Journal: Cardiovascular Diagnosis and Therapy
Article Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing pro-inflammatory macrophage activation
doi: 10.21037/cdt-21-743
Figure Lengend Snippet: Effect of miR-155 inhibition on Cx43 degradation in vivo post-MI and in vitro in hypoxic NRCMs. (A) Representative photomicrographs of Cx43 expression (red staining) in mouse cardiac tissue after MI. Nuclei were counterstained with DAPI. Scale bar, 20 µm. (B) Representative Western blots of Cx43 expression in mouse cardiac tissue after MI. (C) Quantitative analysis of data in (B) (n=5; *, P<0.01 vs. the sham group; $, P<0.05 vs. the MI group). (D-I) Conditioned medium was obtained from LPS-induced BMDMs treated with or without miR-155 antagomir/agomir for 24 h and then applied to cultures of hypoxia-induced NRCMs for 24 h. (D,F,H) Representative Western blots of Cx43 expression. (E,G,I) Quantitative densitometric analysis of data from (D), (F) and (H), respectively [n=3; *, P<0.05 vs. the Con, the hypoxia + medium (LPS + con-antagomir/con-agomir) or the hypoxia + medium (LPS + miR-155 con-agomir) group]. (J-Q) LPS-induced BMDMs were treated with or without si-IL-1β RNA, si-MMP7 RNA or miR-155 agomir for 24 h, and the resulting conditioned medium was applied to hypoxia-induced NRCMs for 24 h. (J,L,N,P) Representative Western blots of IL-1β, MMP7 and Cx43 expression. (K,M,O,Q) Quantitative densitometric analysis of data from (J), (L), (N) and (P), respectively [n=3; *, P<0.05 vs. the si-con or the hypoxia + medium (LPS + con-agomir) group; $, P<0.05 vs. the hypoxia + medium (LPS + si-IL-1β or LPS + si-MMP7) group]. Con, control; Cx43, connexin 43; MI, myocardial infarction; LPS, lipopolysaccharide; BMDMs, bone-marrow-derived macrophages; NRCMs, neonatal mouse cardiomyocytes; IL-1β, interleukin-1β; MMP7, matrix metalloproteinase 7.
Article Snippet: The control con/miR-155-agomir, con/miR-155-antagomir (scrambled sequence), miR-155 antagomir (a 2'-O-methyl + 5' cholesterol-modified miR-155 inhibitor), small interfering (si)RNA control, and siRNAs specific for SOCS1, IL-1β, and MMP7 were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China).
Techniques: Inhibition, In Vivo, In Vitro, Expressing, Staining, Western Blot, Control, Derivative Assay